SCYL2

Across TCGA pan-cancer cohorts, SCYL2 mass-spec protein is linked to patient survival in 8 of 34 cancer types, making it a survival-associated SCYL2 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher SCYL2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SCYL2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and UCEC show a favorable association.

LSCC, UCEC, and LUAD are the cancer types where SCYL2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	All	0.985	0.886	.005	21	view →
UCEC	DFS	Tertile	II,III,IV	1.000	0.417	.005	16	view →
LUAD	OS	Median	II,III,IV	1.000	0.862	.004	13	view →
HNSC	OS	Median	All	0.484	1.000	.038	12	view →
OV	DFS	Quartile	All	0.629	1.000	.046	8	view →
CCRCC	OS	Median	IV	0.150	0.785	.040	4	view →
PDAC	DFS	Quartile	III,IV	0.892	0.361	.030	3	view →
GBM	OS	Median	All	0.247	0.551	.015	2	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

SCYL2–LSCC (DFS)

Open the LSCC breakdown →